The efficacy and safety of irbesartan in primary hypertension even if a dose is missed: Results from the no problem study

Blood Pressure

Volumn 19, Issue SUPPL. 1, 2010, Pages 5-9

  Kabakci, Giray ^a   Kaya, Baris Ergun ^a   Tulumen, Erol ^a   Kocabas, Ugur ^a   Abali, Gulcan ^a   Deveci, Onur ^a   Aytemir, Kudret ^a   Tokgozoglu, Lale ^a   Ozkutlu, Hilmi ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Ambulatory blood pressure measurement; Hypertension; Irbesartan; Missed dose

Indexed keywords

IRBESARTAN;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; BLOOD PRESSURE; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TETRAZOLES;

EID: 77649154848     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.3109/08037050903444099     Document Type: Article

References (14)

1. Pool JL, Guthrie RM, Littlejohn TW 3rd, Raskin P, Shephard AM, Weber MA, et al. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension. Am J Hypertens. 1998;11:462-470.
2. Reeves RA, Lin CS, Kassler-Taub K, Pouleur H. Dose-related effi cacy of irbesartan for hypertension: an integrated analysis. Hypertension. 1998;31:1311-1316.
3. Simon TA, Gelarden RT, Freitag SA, Kassler-Taub KB, Davies R. Safety of irbesartan in the treatment of mild to moderate systemic hypertension. Am J Cardiol. 1998;82: 179-182.
4. Fogari R, Ambrosoli S, Corradi L, Degli Esposti E, Mos L, Nami R, et al. 24-hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring: Irbesartan Multicenter Investigators' Group. J Hypertens. 1997;15:1511-1518.
5. Guthrie R, Saini R, Herman T, Pleskow W, Sprecher D, Collins G. Effi cacy and tolerability of irbesartan, an angiotensin II receptor antagonist, in primary hypertension: a double-blind, placebo-controlled, dose-titration study. Multicentre Investigators. Clin Drug Invest. 1998;15(3):217-227.
6. Burnier M, Hess B, Greminger P, Waeber B. Determinants of persistence in hypertensive patients treated with irbesartan: results of a postmarketing survey. BMC Cardiovasc Disord. 2005;5:13.
7. Kintscher U, Bramlage P, Paar WD, Thoenes M, Unger T. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients. Cardiovasc Diabetol. 2007;6:12.
8. Mancia G, Dell'Oro R, Turri C, Grassi G. Comparison of angiotensin II receptor blockers: impact of missed doses of candesartan cilexetil and losartan in systemic hypertension. Am J Cardiol. 1999;84:28S-34S.
9. Tan KW, Leenen FH. Persistence of anti-hypertensive effect after missed dose of perindopril. Br J Clin Pharmacol. 1999;48:628-630.
10. Hermida RC, Ayala DE, Khder Y, Calvo C. Ambulatory blood pressure-lowering effects of valsartan and enalapril after a missed dose in previously untreated patients with hypertension: a prospective, randomized, open-label, blinded endpoint trial. Clin Ther. 2008;30:108-120.
11. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al.; The task force for the management of arterial hypertension of the European Society of Hypertension, The task force for the management of arterial hypertension of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007; 28:1462-1536.
12. Mancia G, Grassi G. Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens. 2002;20:1461-1464.
13. Düsing R, Weisser B, Mengden T, Vetter H. Changes in antihypertensive therapy--the role of adverse effects and compliance. Blood Press. 1998;7(5-6);313-315.
14. Hernández RH, Armas-Hernández MJ, Chourio JA, Armas-Padilla MC, López L, Alvarez M, et al. Comparative effects of amlodipine and nifedipine GITS during treatment and after missing two doses. Blood Press Monit. 2001; 6(1):47-57.